View More Recent Stories

Oct 15, 2024 02:14PM Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
Oct 15, 2024 01:57PM Exelixis (EXEL) Announces Update on Second Patent Litigation Trial with MSN Laboratories
Oct 15, 2024 11:29AM Exelixis (EXEL) Strength Tied to US Court Ruling in Patent Case vs MSN
Oct 14, 2024 02:33PM Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
Oct 14, 2024 10:57AM Citi Reiterates Buy Rating on Exelixis (EXEL)
Oct 14, 2024 10:57AM Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
Oct 14, 2024 08:02AM Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
Sep 19, 2024 02:46AM UBS Starts Exelixis (EXEL) at Neutral
Sep 16, 2024 02:01PM Citi Reiterates Buy Rating on Exelixis (EXEL)
Sep 16, 2024 08:45AM Exelixis (EXEL) Reports Final Results from Phase 3 Pivotal CABINET Study of Cabozantinib
Sep 16, 2024 07:06AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Sep 16, 2024 04:58AM Citi Reiterates Buy Rating on Exelixis (EXEL)
Sep 4, 2024 09:59AM Exelixis (EXEL) PT Raised to $30 at BofA Securities
Aug 8, 2024 08:22AM Exelixis (EXEL) PT Raised to $33 at Truist Securities
Aug 8, 2024 06:36AM Exelixis (EXEL) PT Raised to $29 at H.C. Wainwright
Aug 6, 2024 04:18PM Exelixis (EXEL) Tops Q2 EPS by 53c; offers guidance
Aug 6, 2024 08:30AM Exelixis (EXEL) Announces FDA Accepted sNDA for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
View More Recent Stories